Image

Physiological Effects of Frontopolar TMS in Alcohol Craving

Physiological Effects of Frontopolar TMS in Alcohol Craving

Recruiting
18-65 years
All
Phase N/A

Powered by AI

Overview

Alcohol dependence is a prevalent and debilitating condition characterized by a chronic inability to control alcohol consumption. Current treatment options offere limited efficacy, and there is a pressing need for innovative approaches. Continuous Theta Burst Stimulation (cTBS) is a form of transcranial magnetic stimulation (TMS) that has shown promise in modulating brain activity associated with craving and addiction. This study aims to explore the effects of cTBS over the left frontopolar cortex on neurobiological and physiological markers of craving in patients with alcohol dependence induced by virtual reality (VR) alcohol cue exposure. Additionally, this study aims to investigate the relationship between changes in physiological craving markers and baseline brain connectivity. The investigators hypothesize that cTBS TMS treatment will reduce physiological markers of craving in patients with alcohol dependence. Additionally, it is expected that baseline structural and functional connectivity will predict the degree of VR-induced heart rate increase after cTBS, providing insights into individual brain network variability in the effect of cTBS.

Description

Alcohol dependence is a prevalent and debilitating condition characterized by a chronic inability to control alcohol consumption despite adverse consequences. Current treatment options have limited efficacy, and there is a pressing need for innovative approaches. Continuous Theta Burst Stimulation (cTBS) is a form of transcranial magnetic stimulation (TMS) that has shown promise in modulating brain activity associated with craving and addiction. This study aims to explore the effects of cTBS over the left frontopolar cortex on neurophysiological markers of craving in patients with alcohol dependence and to investigate the relationship between these effects and baseline brain connectivity.

The objectives of this study are on the one hand to evaluate the impact of cTBS TMS administration over the left frontopolar cortex on neurophysiological craving markers (such as heart rate, skin conductance and skin temperature in a VR-based craving induction) in patients with alcohol dependence and on the other hand to investigate the relationship between baseline structural and functional brain connectivity (as assessed by magnetic resonance imaging; MRI) and the physiological response to craving induction after TMS.

This study aims to include 34 patients diagnosed with alcohol dependence. Inclusion criteria include adults aged 18-65 with an ICD-10 diagnosis of alcohol dependence. Exclusion criteria include severe neurological disorders or contraindications to TMS or MRI.

Participants will receive 15 sessions of cTBS TMS treatment over one week, targeting the left frontopolar cortex. Physiological parameters will be assessed before and after the TMS application using Virtual Reality Cue Exposure and Craving Assessment (VR-CECA). Structural and functional MRI scans will be conducted at baseline to assess brain connectivity.

The primary outcome measure will be the change in heart rate during VR-CECA craving induction. Secondary outcomes include changes in self-reported craving, skin conductance, and temperature during VR-CECA and the correlation between baseline brain connectivity and changes in heart rate increase during VR.

This study hypothesizes that cTBS TMS treatment will reduce neurophysiological markers of craving in patients with alcohol dependence. Additionally, it is expected that baseline structural and functional connectivity will predict the degree of VR-induced heart rate increase after cTBS, providing insights into individual brain network variability in the effect of cTBS. TMS is generally well-tolerated, with the most common side effects being mild headaches and scalp discomfort.

This study aims to advance the understanding of the neurophysiological mechanisms underlying craving in alcohol dependence and to identify potential biomarkers for predicting craving reductions. If successful, this could lead to more targeted and effective interventions for alcohol dependence, ultimately improving patient outcomes.

Eligibility

Inclusion Criteria:

  • adults aged 18-65
  • ICD-10 diagnosis of alcohol dependence
  • Ability to give consent
  • Sinus rhythm in ECG

Exclusion Criteria:

  • Current psychotic symptoms in patients with psychotic disorders (F20, F23, F10.5)
  • Contraindication against TMS or MRI
  • Severe neurological disorders such as epilepsy, stroke, neuroinflammatory disorders (e.g., multiple sclerosis). A history of seizures only in the context of alcohol withdrawal does not represent a contraindication, unless the seizure happened in the last 3 weeks before study inclusion.
  • Acute withdrawal symptoms (CIWA-Ar > 5)

Study details
    Alcohol Addiction

NCT07064590

Goethe University

13 September 2025

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.